FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209064864> ?p ?o ?g. }

• W3209064864 endingPage "861" @default.
• W3209064864 startingPage "852" @default.
• W3209064864 abstract "BackgroundAlthough intravenous immunoglobulin (IVIG) is effective therapy for Kawasaki disease, 10–20% of patients have recrudescent fever as a sign of persistent inflammation and require additional treatment. We aimed to compare infliximab with a second infusion of IVIG for treatment of resistant Kawasaki disease.MethodsIn this multicentre comparative effectiveness trial, patients (aged 4 weeks to 17 years) with IVIG resistant Kawasaki disease and fever at least 36 h after completion of their first IVIG infusion were recruited from 30 hospitals across the USA. Patients were randomly assigned (1:1) to second IVIG (2 g/kg over 8–12 h) or intravenous infliximab (10 mg/kg over 2 h without premedication), by using a randomly permuted block randomisation design with block size of two or four. Patients with fever 24 h to 7 days following completion of first study treatment crossed over to receive the other study treatment. The primary outcome measure was resolution of fever at 24 h after initiation of study treatment with no recurrence of fever attributed to Kawasaki disease within 7 days post-discharge. Secondary outcome measures included duration of fever from enrolment, duration of hospitalisation after randomisation, and changes in markers of inflammation and coronary artery Z score. Efficacy was analysed in participants who received treatment and had available outcome values. Safety was analysed in all randomised patients who did not withdraw consent. This clinical trial is registered with ClinicalTrials.gov, NCT03065244.FindingsBetween March 1, 2017, and Aug 31, 2020, 105 patients were randomly assigned to treatment and 103 were included in the intention-to-treat population (54 in the infliximab group, 49 in the second IVIG group). Two patients randomised to infliximab did not receive allocated treatment. The primary outcome was met by 40 (77%) of 52 patients in the infliximab group and 25 (51%) of 49 patients in the second IVIG infusion group (odds ratio 0·31, 95% CI 0·13–0·73, p=0·0076). 31 patients with fever beyond 24 h received crossover treatment: nine (17%) in the infliximab group received second IVIG and 22 (45%) in second IVIG group received infliximab (p=0·0024). Three patients randomly assigned to infliximab and two to second IVIG with fever beyond 24h did not receive crossover treatment. Mean fever days from enrolment was 1·5 (SD 1·4) for the infliximab group and 2·5 (2·5) for the second IVIG group (p=0·014). Mean hospital stay was 3·2 days (2·1) for the infliximab group and 4·5 days (2·5) for the second IVIG group (p<0·001). There was no difference between treatment groups for markers of inflammation or coronary artery outcome. 24 (44%) of 54 patients in the infliximab group and 33 (67%) of 49 in the second IVIG group had at least one adverse event. A drop in haemoglobin concentration of at least 2g/dL was seen in 19 (33%) of 58 patients who received IVIG as either their first or second study treatment (three of whom required transfusion) and in three (7%) of 43 who received only infliximab (none required transfusion; p=0·0028). Haemolytic anaemia was the only serious adverse events deemed definitely or probably related to study treatment, and was reported in nine (15%) of 58 patients who received IVIG as either their first or second study treatment and none who received infliximab only.InterpretationInfliximab is a safe, well tolerated, and effective treatment for patients with IVIG resistant Kawasaki disease, and results in shorter duration of fever, reduced need for additional therapy, less severe anaemia, and shorter hospitalisation compared with second IVIG infusion.FundingPatient Centered Outcomes Research Institute." @default.
• W3209064864 created "2021-11-08" @default.
• W3209064864 creator A5000822487 @default.
• W3209064864 creator A5002560378 @default.
• W3209064864 creator A5003533839 @default.
• W3209064864 creator A5005970364 @default.
• W3209064864 creator A5006764971 @default.
• W3209064864 creator A5006781619 @default.
• W3209064864 creator A5007683141 @default.
• W3209064864 creator A5008419280 @default.
• W3209064864 creator A5009913385 @default.
• W3209064864 creator A5013153304 @default.
• W3209064864 creator A5013510871 @default.
• W3209064864 creator A5015260206 @default.
• W3209064864 creator A5016665201 @default.
• W3209064864 creator A5018505180 @default.
• W3209064864 creator A5021426744 @default.
• W3209064864 creator A5023838289 @default.
• W3209064864 creator A5026626377 @default.
• W3209064864 creator A5027897203 @default.
• W3209064864 creator A5030356854 @default.
• W3209064864 creator A5031075999 @default.
• W3209064864 creator A5035524193 @default.
• W3209064864 creator A5036208440 @default.
• W3209064864 creator A5036428452 @default.
• W3209064864 creator A5036681587 @default.
• W3209064864 creator A5037514446 @default.
• W3209064864 creator A5038786903 @default.
• W3209064864 creator A5040035646 @default.
• W3209064864 creator A5040070345 @default.
• W3209064864 creator A5042837100 @default.
• W3209064864 creator A5043719295 @default.
• W3209064864 creator A5045341262 @default.
• W3209064864 creator A5048642882 @default.
• W3209064864 creator A5050284606 @default.
• W3209064864 creator A5052358762 @default.
• W3209064864 creator A5055220125 @default.
• W3209064864 creator A5060698311 @default.
• W3209064864 creator A5065281648 @default.
• W3209064864 creator A5065297743 @default.
• W3209064864 creator A5065585077 @default.
• W3209064864 creator A5066988994 @default.
• W3209064864 creator A5067173864 @default.
• W3209064864 creator A5067319455 @default.
• W3209064864 creator A5069964511 @default.
• W3209064864 creator A5070494008 @default.
• W3209064864 creator A5072572343 @default.
• W3209064864 creator A5074548875 @default.
• W3209064864 creator A5075483967 @default.
• W3209064864 creator A5076088778 @default.
• W3209064864 creator A5076801915 @default.
• W3209064864 creator A5077410583 @default.
• W3209064864 creator A5078067277 @default.
• W3209064864 creator A5078124422 @default.
• W3209064864 creator A5078156253 @default.
• W3209064864 creator A5080360375 @default.
• W3209064864 creator A5084519348 @default.
• W3209064864 creator A5089795773 @default.
• W3209064864 date "2021-12-01" @default.
• W3209064864 modified "2023-10-18" @default.
• W3209064864 title "Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial" @default.
• W3209064864 cites W1963550372 @default.
• W3209064864 cites W1963598954 @default.
• W3209064864 cites W1976197580 @default.
• W3209064864 cites W1996936225 @default.
• W3209064864 cites W2047539120 @default.
• W3209064864 cites W2048310854 @default.
• W3209064864 cites W2072371345 @default.
• W3209064864 cites W2079838020 @default.
• W3209064864 cites W2091250847 @default.
• W3209064864 cites W2092491495 @default.
• W3209064864 cites W2109450728 @default.
• W3209064864 cites W2142795619 @default.
• W3209064864 cites W2152621561 @default.
• W3209064864 cites W2212818630 @default.
• W3209064864 cites W2315160100 @default.
• W3209064864 cites W2329101550 @default.
• W3209064864 cites W2331124118 @default.
• W3209064864 cites W2417265690 @default.
• W3209064864 cites W2604027935 @default.
• W3209064864 cites W2767198624 @default.
• W3209064864 cites W2772776282 @default.
• W3209064864 cites W2796440222 @default.
• W3209064864 cites W2805052095 @default.
• W3209064864 cites W2886032916 @default.
• W3209064864 cites W2893477505 @default.
• W3209064864 cites W2994631339 @default.
• W3209064864 cites W3014550493 @default.
• W3209064864 cites W3045583280 @default.
• W3209064864 cites W3113071757 @default.
• W3209064864 doi "https://doi.org/10.1016/s2352-4642(21)00270-4" @default.
• W3209064864 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34715057" @default.
• W3209064864 hasPublicationYear "2021" @default.
• W3209064864 type Work @default.
• W3209064864 sameAs 3209064864 @default.
• W3209064864 citedByCount "30" @default.
• W3209064864 countsByYear W32090648642022 @default.
• W3209064864 countsByYear W32090648642023 @default.

• next